Key result
Elevated MPO and hs-CRP strongly correlate with increased CIMT and reduced FMD in metabolic syndrome.
Why the study?
Cardiovascular disorders are linked to myeloperoxidase and hs-CRP, prompting evaluation of both biomarkers alongside subclinical atherosclerosis in metabolic syndrome patients.
Cross-Sectional (n=75)
No
Elevated serum levels of MPO and hs-CRP strongly correlate with increased carotid intima-media thickness and reduced flow-mediated dilation, suggesting their utility as biomarkers for subclinical atherosclerosis in metabolic syndrome.
Supports MPO and hs-CRP as potential biomarkers of subclinical atherosclerosis in metabolic syndrome; hypothesis-generating, requires prospective validation.
Cardiovascular disorders have been linked to myeloperoxidase, an enzyme generated from leukocytes. MPO creates an antibacterial system and has been many correlations between MPO, hs-CRP and cardiovascular disease. The present study has aimed to assess MPO, hs-CRP and subclinical atherosclerosis in metabolic syndrome patients by using FMD and CIMT parameters. 75 metabolic syndrome affected patients had defined as per the criteria of IDF (International Diabetes Federation) which had been in this study. In addition, ultrasound doppler had been employed for determining the carotid intima medial thickness for both right and left (left and right CIMT) and brachial artery FMD. By employing the Immunoassay MPO and hs-CRP ultrasensitive ELISA kit, the concentration of MPO and hs-CRP is measured. A positive link between MPO with CIMT right and left (r value of right CIMT=0.723, p <0.05 and left CIMT r=0.712, p<0.01), hs-CRP with CIMT right and left (r value of right CIMT=0.613, p<0.05and left CIMT r=0.64, p<0.01)and a significant inverse correlation between MPO with FMD (r= -0.319,p<0.05), hs-CRP with FMD (r= -0.304,p<0.01) in metabolic syndrome patients. Serum MPO and hs-CRP is positively linked with subclinical atherosclerosis in metabolic syndrome patients. According to this finding, understanding the mechanism behind the risk factors for cardiovascular disease can be aided by the development of new molecular markers for metabolic syndrome and subclinical atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Beautlin et al. (2023) conducted a cross-sectional in Metabolic Syndrome (n=75). Serum MPO and hs-CRP measurement was evaluated on Correlation of MPO with right Carotid Intima-Media Thickness (CIMT) (r=0.723, p=<0.01). Serum myeloperoxidase and hs-CRP levels were positively correlated with right carotid intima-media thickness (r=0.723 and r=0.613, respectively) and inversely correlated with flow-mediated dilation in metabolic syndrome patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: